STE · News · 20260805N
Guidance / Outlook
STERIS plc · 2026-08-05 · Importance 44 · Surprise 24 · In source text
STERIS reaffirmed its fiscal 2027 revenue and adjusted earnings-per-share guidance after reporting first-quarter results. Management expects the North Carolina chemistry investment to generate a significant return on invested capital within three to five years. Capital expenditure projections were increased to reflect the $600 million facility, while free cash flow expectations were slightly lowered because of the investment and restructuring program. Analysts also expect a recovery in Applied Sterilization Technologies services during the second half of fiscal 2027.
Key facts
- Stock Titan reported STERIS reaffirmed its full-year fiscal 2027 guidance while increasing capital expenditure projections and lowering free cash flow expectations due to the new investment. source
- STERIS reaffirmed its fiscal 2027 full-year revenue and adjusted earnings-per-diluted-share guidance after Q1 results. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | probable | — | Stock Titan reported STERIS reaffirmed its full-year fiscal 2027 guidance while increasing capital expenditure projections and lowering… |